Home > Journals > Minerva Urology and Nephrology > Past Issues > Minerva Urologica e Nefrologica 2018 February;70(1) > Minerva Urologica e Nefrologica 2018 February;70(1):95-101

CURRENT ISSUE
 

JOURNAL TOOLS

Publishing options
eTOC
To subscribe PROMO
Submit an article
Recommend to your librarian
 

ARTICLE TOOLS

Publication history
Reprints
Permissions
Cite this article as
Share

 

ORIGINAL ARTICLE   Free accessfree

Minerva Urologica e Nefrologica 2018 February;70(1):95-101

DOI: 10.23736/S0393-2249.17.02869-7

Copyright © 2017 EDIZIONI MINERVA MEDICA

language: English

Clinical observation of umbilical cord mesenchymal stem cell transplantation for treating patients receiving peritoneal dialysis

Hong-Ying JIANG 1, Jia-Ping WANG 2, Yi-Hua BAI 1 , Min YANG 1, Yi ZENG 1, Yun-Juan LIAO 1, Zhen-Kun HE 1

1 Department of Nephrology, the Second Hospital Affiliated Kunming Medical University, Kunming, China; 2 Department of Radiology, the Second Affiliated Hospital of Kunming Medical University, Kunming, China


PDF


BACKGROUND: This study aims to observe the outcome and safety of umbilical cord-mesenchymal stem cell (UC-MSC) treatment for continuous ambulatory peritoneal dialysis (CAPD) patients.
METHODS: A total of 24 CAPD patients, who underwent UC-MSC treatment from June 2011 to December 2012, were selected for this study. These patients were followed up until June 2015.
RESULTS: Results revealed a significant increase in hemoglobin, erythropoietin and albumin levels, a decrease in C-reactive protein levels, and marked improvement in cystatin C and urine volume within three months after UC-MSC transplantation; and the difference was statistically significant (P<0.05). However, the difference in residual glomerular filtration rate, serum creatinine, peritoneal KT/V and remnant kidney KT/V was not statistically significant (P>0.05).
CONCLUSIONS: Clinical indicators of patients with CAPD can be partially improved through UC-MSC treatment.


KEY WORDS: Umbilical cord - Mesenchymal stromal cells - Peritoneal dialysis - Therapy - C-reactive protein - Erythropoietin

top of page